Hsbc Holdings PLC Invests $3.63 Million in PROCEPT BioRobotics Corporation $PRCT

Hsbc Holdings PLC bought a new position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the second quarter, Holdings Channel reports. The firm bought 160,586 shares of the company’s stock, valued at approximately $3,626,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its holdings in PROCEPT BioRobotics by 994.5% during the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock valued at $27,000 after buying an additional 1,084 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after acquiring an additional 746 shares in the last quarter. Center for Financial Planning Inc. bought a new position in shares of PROCEPT BioRobotics during the 4th quarter valued at approximately $40,000. Cache Advisors LLC bought a new position in shares of PROCEPT BioRobotics during the 1st quarter valued at approximately $42,000. Finally, Essential Partners LLC grew its holdings in shares of PROCEPT BioRobotics by 7,071.4% in the first quarter. Essential Partners LLC now owns 2,008 shares of the company’s stock valued at $50,000 after purchasing an additional 1,980 shares in the last quarter. 89.46% of the stock is owned by institutional investors.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms, including Kaplan Fox, Rosen Law Firm and Hagens Berman, announced or reiterated that a securities class action has been filed on behalf of investors who purchased PROCEPT shares from February 28, 2024, through February 25, 2026. Investors seeking to serve as lead plaintiff must act by September 22, 2026. Kaplan Fox class-action notice
• Negative Sentiment: The complaint reportedly alleges that PROCEPT understated weakness in unit handpiece sales and failed to disclose elevated customer inventory, while using repeated late-quarter bulk discounts to pull demand forward. The allegations concern potential violations of federal securities laws and could increase litigation costs, reputational risk and investor uncertainty; they have not been proven in court. Hagens Berman PROCEPT investor alert
• Negative Sentiment: The unusually high number of law-firm solicitations over the past two days keeps attention focused on the lawsuit and the company’s prior sales and inventory disclosures. Although the notices do not introduce a new financial result or regulatory action, continued headlines may weigh on sentiment and limit the stock’s recovery.

Insider Activity

In other PROCEPT BioRobotics news, CEO Larry L. Wood bought 23,900 shares of the company’s stock in a transaction on Friday, August 7th. The stock was acquired at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the transaction, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at approximately $498,315. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 1,000 shares of company stock worth $28,480 in the last ninety days. 4.00% of the stock is owned by insiders.

PROCEPT BioRobotics Trading Up 1.1%

Shares of PRCT opened at $20.83 on Friday. The company’s fifty day simple moving average is $20.32 and its 200-day simple moving average is $23.93. The company has a market cap of $1.19 billion, a P/E ratio of -10.74 and a beta of 0.89. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. PROCEPT BioRobotics Corporation has a twelve month low of $16.67 and a twelve month high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The firm had revenue of $94.50 million for the quarter, compared to analysts’ expectations of $92.77 million. During the same period in the prior year, the firm posted ($0.35) earnings per share. PROCEPT BioRobotics’s revenue for the quarter was up 19.3% on a year-over-year basis. As a group, analysts expect that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

Analysts Set New Price Targets

PRCT has been the topic of a number of recent research reports. William Blair downgraded shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Leerink Partners downgraded shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $31.00 to $29.00 in a report on Thursday, June 11th. TD Cowen decreased their target price on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Citigroup downgraded shares of PROCEPT BioRobotics to a “hold” rating in a report on Thursday, July 2nd. Finally, Wells Fargo & Company lowered PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price target for the company. in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, PROCEPT BioRobotics presently has a consensus rating of “Hold” and an average price target of $28.00.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.